These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31979381)

  • 1. Conversion to Everolimus was Beneficial and Safe for Fast and Slow Tacrolimus Metabolizers After Renal Transplantation.
    Thölking G; Gillhaus NH; Schütte-Nütgen K; Pavenstädt H; Koch R; Suwelack B; Reuter S
    J Clin Med; 2020 Jan; 9(2):. PubMed ID: 31979381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved Kidney Allograft Function after Early Conversion of Fast IR-Tac Metabolizers to LCP-Tac.
    Thölking G; Tosun-Koç F; Jehn U; Koch R; Pavenstädt H; Suwelack B; Reuter S
    J Clin Med; 2022 Feb; 11(5):. PubMed ID: 35268380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased renal function decline in fast metabolizers using extended-release tacrolimus after kidney transplantation.
    Thölking G; Filensky B; Jehn U; Schütte-Nütgen K; Koch R; Kurschat C; Pavenstädt H; Suwelack B; Reuter S; Kuypers D
    Sci Rep; 2021 Aug; 11(1):15606. PubMed ID: 34341448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fast Tac Metabolizers at Risk ⁻ It is Time for a C/D Ratio Calculation.
    Schütte-Nütgen K; Thölking G; Steinke J; Pavenstädt H; Schmidt R; Suwelack B; Reuter S
    J Clin Med; 2019 Apr; 8(5):. PubMed ID: 31035422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Tacrolimus Metabolism Rate and Dyslipidemia after Kidney Transplantation.
    Thölking G; Schulte C; Jehn U; Schütte-Nütgen K; Pavenstädt H; Suwelack B; Reuter S
    J Clin Med; 2021 Jul; 10(14):. PubMed ID: 34300232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tacrolimus Concentration/Dose Ratio is Associated with Renal Function After Liver Transplantation.
    Thölking G; Siats L; Fortmann C; Koch R; Hüsing A; Cicinnati VR; Gerth HU; Wolters HH; Anthoni C; Pavenstädt H; Suwelack B; Schmidt HH; Kabar I
    Ann Transplant; 2016 Mar; 21():167-79. PubMed ID: 27003330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The tacrolimus metabolism rate influences renal function after kidney transplantation.
    Thölking G; Fortmann C; Koch R; Gerth HU; Pabst D; Pavenstädt H; Kabar I; Hüsing A; Wolters H; Reuter S; Suwelack B
    PLoS One; 2014; 9(10):e111128. PubMed ID: 25340655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanistic analyses in kidney transplant recipients prospectively randomized to two steroid free regimen-Low dose Tacrolimus with Everolimus versus standard dose Tacrolimus with Mycophenolate Mofetil.
    Traitanon O; Mathew JM; Shetty A; Bontha SV; Maluf DG; El Kassis Y; Park SH; Han J; Ansari MJ; Leventhal JR; Mas V; Gallon L
    PLoS One; 2019; 14(5):e0216300. PubMed ID: 31136582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tacrolimus and Everolimus de novo versus minimization of standard dosage of Tacrolimus provides a similar renal function at one year after liver transplantation: a case-control matched-pairs analysis.
    Mocchegiani F; Montalti R; Nicolini D; Svegliati Baroni G; Benedetti A; Risaliti A; Vivarelli M
    Ann Transplant; 2014 Oct; 19():545-50. PubMed ID: 25347718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Elective Conversion From Sotrastaurin (STN) to Tacrolimus (TAC) or Mycophenolate (MPS) in Stable Kidney Transplant Recipients.
    Hannun P; Felipe C; Ferreira A; Sandes-Freitas T; Cristelli M; Aguiar W; Franco M; Campos E; Gerbase de Lima M; Tedesco-Silva H; Medina-Pestana J
    Ther Drug Monit; 2016 Jun; 38(3):293-9. PubMed ID: 26919549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Switch From Tacrolimus to Everolimus After Liver Transplantation: Outcomes at 2 Years.
    Saliba F; Duvoux C; Dharancy S; Dumortier J; Calmus Y; Gugenheim J; Kamar N; Salamé E; Neau-Cransac M; Vanlemmens C; Durand F; Pageaux G; Leroy V; Hardwigsen J; Gharbi H; Masson C; Tindel M; Conti F
    Liver Transpl; 2019 Dec; 25(12):1822-1832. PubMed ID: 31631501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tacrolimus reduction with everolimus addition for calcineurin inhibitor-induced arteriolopathy in kidney allografts.
    Miura M; Higashiyama H; Fukasawa Y; Itoh Y; Tamaki T
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():58-60. PubMed ID: 26031588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled randomized study comparing the cardiovascular profile of everolimus with tacrolimus in renal transplantation.
    Cruzado JM; Pascual J; Sánchez-Fructuoso A; Serón D; Díaz JM; Rengel M; Oppenheimer F; Hernández D; Paravisini A; Saval N; Morales JM;
    Transpl Int; 2016 Dec; 29(12):1317-1328. PubMed ID: 27648523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Low Tacrolimus Concentration-to-Dose Ratio Increases Calcineurin Inhibitor Nephrotoxicity and Cytomegalovirus Infection Risks in Kidney Transplant Recipients: A Single-Center Study in Japan.
    Tomizawa M; Hori S; Inoue K; Nishimura N; Nakai Y; Miyake M; Yoneda T; Fujimoto K
    Transplant Proc; 2023; 55(1):109-115. PubMed ID: 36623961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tacrolimus: Influence of the Posttransplant Concentration/Dose Ratio on Kidney Graft Function in a Two-Year Follow-Up.
    Nowicka M; Górska M; Nowicka Z; Edyko K; Edyko P; Wiślicki S; Zawiasa-Bryszewska A; Strzelczyk J; Matych J; Kurnatowska I
    Kidney Blood Press Res; 2019; 44(5):1075-1088. PubMed ID: 31522184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot conversion trial from mycophenolic acid to everolimus in ABO-incompatible kidney-transplant recipients with BK viruria and/or viremia.
    Belliere J; Kamar N; Mengelle C; Allal A; Sallusto F; Doumerc N; Game X; Congy-Jolivet N; Esposito L; Debiol B; Rostaing L
    Transpl Int; 2016 Mar; 29(3):315-22. PubMed ID: 26575959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
    Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
    Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of everolimus in reducing cytomegalovirus events in kidney transplant recipients on steroid-avoidance strategy: 3-year follow-up of a randomized clinical trial.
    de Sandes-Freitas TV; Pinheiro PMA; Sales MLMBO; Girão CM; Campos ÉF; Esmeraldo RM
    Transpl Int; 2018 Dec; 31(12):1345-1356. PubMed ID: 29969826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tacrolimus Concentration/Dose Ratio: A Tool for Guiding Tacrolimus Dosage Post-renal Transplantation.
    Shenoy MT; Manavalan J; A H; K S; Mohanty PK
    Cureus; 2024 Feb; 16(2):e53421. PubMed ID: 38435193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.